[go: up one dir, main page]

MX2020007162A - Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina. - Google Patents

Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.

Info

Publication number
MX2020007162A
MX2020007162A MX2020007162A MX2020007162A MX2020007162A MX 2020007162 A MX2020007162 A MX 2020007162A MX 2020007162 A MX2020007162 A MX 2020007162A MX 2020007162 A MX2020007162 A MX 2020007162A MX 2020007162 A MX2020007162 A MX 2020007162A
Authority
MX
Mexico
Prior art keywords
disorders
etifoxine
methods
seizure
treating developmental
Prior art date
Application number
MX2020007162A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020007162A publication Critical patent/MX2020007162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo y/o trastornos convulsivos con etifoxina, un análogo deuterado de etifoxina, o una sal, solvato o profármaco farmacéuticamente aceptable del mismo. Los métodos proporcionan composiciones terapéuticas que se pueden usar para mejorar uno o más síntomas del trastorno de desarrollo y/o trastorno convulsivo.
MX2020007162A 2017-09-26 2018-09-25 Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina. MX2020007162A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563155P 2017-09-26 2017-09-26
US15/961,002 US10420773B2 (en) 2017-09-26 2018-04-24 Methods of treating developmental disorders and/or seizure disorders with etifoxine
PCT/US2018/052542 WO2019067389A1 (en) 2017-09-26 2018-09-25 METHODS OF TREATING DEVELOPMENTAL DISORDERS AND / OR EPILEPTIC DISORDERS WITH ETIFOXIN

Publications (1)

Publication Number Publication Date
MX2020007162A true MX2020007162A (es) 2020-08-17

Family

ID=65807015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007162A MX2020007162A (es) 2017-09-26 2018-09-25 Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.

Country Status (5)

Country Link
US (2) US10420773B2 (es)
EP (1) EP3672599A4 (es)
CA (1) CA3076900A1 (es)
MX (1) MX2020007162A (es)
WO (1) WO2019067389A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US20220265666A1 (en) * 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
CN120390643A (zh) * 2022-10-24 2025-07-29 加巴疗法股份有限公司 艾替伏辛的氘代类似物及施用而没有代谢自身诱导的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
US20080039453A1 (en) 2006-03-20 2008-02-14 David Putman Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
EP2007741A1 (en) * 2006-03-20 2008-12-31 Xytis Inc. Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2013006857A1 (en) * 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
US10080755B2 (en) 2015-03-20 2018-09-25 Anvyl, Llc Deuterated analogs of etifoxine, their derivatives and uses thereof
CA3002831C (en) 2015-10-22 2024-04-16 Cavion, Inc. Methods for treating angelman syndrome and related disorders
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine

Also Published As

Publication number Publication date
US10420773B2 (en) 2019-09-24
EP3672599A4 (en) 2021-06-09
US20190091231A1 (en) 2019-03-28
US20200000813A1 (en) 2020-01-02
WO2019067389A1 (en) 2019-04-04
CA3076900A1 (en) 2019-04-04
US10925879B2 (en) 2021-02-23
EP3672599A1 (en) 2020-07-01

Similar Documents

Publication Publication Date Title
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MX384908B (es) Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
MX2018006223A (es) Moduladores de ror-gamma.
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2023009631A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2019000677A (es) Células miméticas de células b.
EP3710010A4 (en) USE OF HM4DI IN TREATMENT OF SEQUENCE DISEASES
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX375860B (es) Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.
BR112016028081A2 (pt) Novos compostos como agentes antituberculares
MX384045B (es) (+)-azasetrón para su uso en el tratamiento de trastornos del oído.
MX2021003302A (es) Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.